
The role of public health in precision medicine – an interview with Kelly Gebo
In this interview we speak to Kelly Gebo, Chief Medical and Scientific Officer for the…
In this interview we speak to Kelly Gebo, Chief Medical and Scientific Officer for the…
In October 2019 researchers from Brazil identified a new parasite, which presented with similar symptoms to visceral leishmaniasis. To discover more about this novel parasite and other parasitic diseases in Brazil, we interviewed Sandra Maruyama from the Federal University of São Carlos (UFSCar; São Paulo, Brazil) about her research and the future of this field.
Researchers recently profiled the single-cell transcriptomes of thousands of individual parasites to provide the first high-resolution atlas of malaria parasite gene expression across the lifecycle.
Multidrug resistance to two antimalarials, used in combination as a first-line therapy, has been found using genomic surveillance to be rapidly spreading throughout Asia.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
Scientists at California State University, Fresno have identified multidrug resistance in six probiotic Bacillus strains to several antibiotics through genetic analysis.
A study has revealed genetic variants associated with differing levels of protective antibodies produced after routine immunizations.
A global genomic survey of Streptococcus pneumoniae has identified 621 strains across 50 countries and has highlighted how the bacteria can evolve in response to vaccination.
In this interview we speak with Sarah Earle from the University of Oxford (UK) about her use of GWAS to understand more about Neisseria meningitidis and its transition from an asymptomatic commensal to an invasive pathogen.
A cohort of scientists from the Wellcome Sanger Institute, the University of Cambridge, the Peter Doherty Institute for Infection and Immunity and the University of Queensland have identified novel targets using DNA sequencing, bringing research one step closer to developing a universal vaccine against Group A Streptococcus.